Cerevel Therapeutics Holdings Inc Ordinary Shares CERE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CERE is a good fit for your portfolio.
News
-
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
-
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
-
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MGRC, SNCE, VINE, CERE
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE)
-
Pfizer shares downgraded as patent expirations loom
-
Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion
-
Trending: AbbVie to Buy Cerevel for $45 a Share
-
There's a new market dynamic heading into payrolls report, Goldman trading expert says
Trading Information
- Previous Close Price
- $42.07
- Day Range
- $41.93–42.49
- 52-Week Range
- $19.59–43.59
- Bid/Ask
- $42.48 / $42.47
- Market Cap
- $7.71 Bil
- Volume/Avg
- 680,906 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 334
- Website
- https://www.cerevel.com
Comparables
Valuation
|
Metric
|
CERE
|
ITCI
|
RYTM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 11.43 | 11.92 | 13.90 |
Price/Sales | — | 15.17 | 29.58 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CERE
|
ITCI
|
RYTM
|
|---|---|---|---|
Quick Ratio | 10.81 | 4.95 | 5.27 |
Current Ratio | 10.92 | 5.41 | 5.58 |
Interest Coverage | −44.07 | — | −13.26 |
Quick Ratio
CERE
ITCI
RYTM
Profitability
|
Metric
|
CERE
|
ITCI
|
RYTM
|
|---|---|---|---|
Return on Assets (Normalized) | −38.51% | −13.47% | −46.12% |
Return on Equity (Normalized) | −84.00% | −15.88% | −76.97% |
Return on Invested Capital (Normalized) | −49.36% | −17.96% | −76.40% |
Return on Assets
CERE
ITCI
RYTM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tkfslmvlc | Lvwv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gkxtqgm | Fkzcvw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rhpshpl | Crffx | $97.8 Bil | |
MRNA
| Moderna Inc | Syslnrb | Zcfxb | $41.3 Bil | |
ARGX
| argenx SE ADR | Zsyllhdgs | Dvbth | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fncklfsl | Mjx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgltprbnj | Zkcfd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wfxchplmz | Llgtxz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gymjrxxgdc | Bcxqm | $12.5 Bil | |
INCY
| Incyte Corp | Dxhtwndx | Ywczss | $11.6 Bil |